Competitive Revision Supplements to Existing AHRQ Patient Centered Outcomes Research (PCOR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement – Clinical Trial Optional)

0
159

Funding Opportunity ID: 326591
Opportunity Number: PA-20-072
Opportunity Title: Competitive Revision Supplements to Existing AHRQ Patient Centered Outcomes Research (PCOR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement – Clinical Trial Optional)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
CFDA Number(s): 93.226
Eligible Applicants: State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. See FOA for full eligibility details.
Agency Code: HHS-AHRQ
Agency Name: Department of Health and Human Services
Agency for Health Care Research and Quality
Posted Date: Apr 29, 2020
Close Date: May 31, 2020
Last Updated Date: Apr 29, 2020
Award Ceiling: $0
Award Floor: $0
Estimated Total Program Funding: $15,000,000
Expected Number of Awards:
Description: The Agency for Healthcare Research and Quality (AHRQ) hereby notifies grantees holding active AHRQ awards that were funded under the PCOR FOAs, (see referenced FOAs under: Part 1. Overview Information, Activity Code), that funds are available for competitive revisions to meet immediate needs to help address timely health system and healthcare professional response to the COVID-19 public health crisis. This FOA does not include grants that were awarded using AHRQ Health Service Research (HSR) dollars (please see FOA number PA-20-070, which is directed toward those grants). It is expected that competitive revision supplement requests will capitalize on the expertise of grant personnel and the institutional environment to expand the specific aims of the on-going research to develop high-impact new knowledge concerning COVID-19. The proposed projects must support dissemination of comparative clinical effectiveness research findings or the training of researchers in the methods used to conduct such research. Funding will be available in Fiscal Year 2020.
Version: 1





Visit the Official Webpage For More Details on Competitive Revision Supplements to Existing AHRQ Patient Centered Outcomes Research (PCOR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement – Clinical Trial Optional)

LEAVE A REPLY

Please enter your comment!
Please enter your name here